Inhibition of IGF-IR/IGF-I expression by nucleic acid based strategies could also be clinically useful as shown by a pilot study of ex-vivo treatment of malignant astrocytomas with antisense oligonucleotides targeted to IGF-IR [34]. The gene discussed is IGF1; the disease is astrocytoma (excluding glioblastoma).